10/21/2026
WPS Oncology Related LCD Updates
October Updates
October 2026 Local Coverage Determination (LCD) and Billing and Coding Article Updates
We updated the following Local Coverage Determinations (LCDs) and Billing and Coding Articles for October 2026. The full article on our website details additional information on these updates.
Please note: Our LCDs and Billing and Coding/Coverage articles will reflect these changes on October 1, 2026
New Policies/Articles – We created no new policies/articles for October 2026.
Retired Policies/Articles – We retired the following policies/articles for October 2026 – Effective October 11, 2026:
- Billing and Coding: MolDx: Genetic Testing for Hypercoagulability/Thrombophilia (Factor V Leiden, Factor II Prothrombin, And MTHFR)
- MolDx: Genetic Testing for Hypercoagulability/Thrombophilia (Factor V Leiden, Factor II Prothrombin, and MTHFR)
Revised Policies/Articles – We revised the following policies/articles for October 2026 –Effective as Indicated
- 2027 ICD-10-CM Code Updates – Effective October 1, 2026
- Billing and Coding: Facet Joint Interventions for Pain Management – Effective September 17, 2026
- Billing and Coding: Implantable Automatic Defibrillators – Effective October 1, 2026
- Billing and Coding: Implantable Continuous Glucose Monitors (I-CGM)– Effective September 10, 2026
- Billing and Coding: MolDx: Biomarker Testing in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis – Effective October 1, 2026
- Billing and Coding: MolDx: Biomarkers in Cardiovascular Risk Assessment – Effective October 1, 2026
- Billing and Coding: MolDx: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis – Effective October 1, 2026
- Billing and Coding: MolDx: Next-Generation Sequencing for Solid Tumors – Effective September 24, 2026
- Billing and Coding: MolDx: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies – Effective October 1, 2026
|
Proposed Local Coverage Determinations (LCDs), Comment Periods, and Upcoming Meetings
The following proposed LCDs are open for comment:
|
|
|
LCD Database ID Number
|
Proposed LCD Title
|
Contractor Medical Director (CMD)
|
Open Comment Period
|
|
DL40470
|
MolDX: Transcriptional Biomarkers for Therapeutic Decision-Making in Renal Carcinoma
|
Dr. Denise Nachodsky
|
9/24/2026 through 11/7/2026
|
|
DL40472
|
MolDX: NGS for Hematologic Malignancies and Suspected Hematologic Malignancies
|
Dr. Denise Nachodsky
|
9/24/2026 through 11/7/2026
|
|
DL40474
|
MolDX: Genome-Wide Molecular Methodologies for the Detection of Copy Number Alterations and Structural Variants in Hematologic Neoplasms
|
Dr. Denise Nachodsky
|
9/24/2026 through 11/7/2026
|
|
|
|
The proposed LCDs are available on the Medicare Coverage Database starting 9/24/2026.
Open Comments
We will accept comments on these LCDs during the Open Comment period indicated above. Please send all comments to medicarepolicycomments@wpsic.com and include the topic of the LCD in the email subject line. Please include published scientific studies or literature to support any changes to the proposed coverage guidelines. We accept .docx and .pdf file types. For security purposes, do not send encrypted emails, compressed attachments, or web links.
Upcoming Proposed LCD Meetings
WPS will present the proposed LCDs during our upcoming Open Meeting and our Contractor Advisory Committee (CAC) Engagement Meeting.
Proposed LCD Open Meetings are for anyone wishing to provide input about LCDs currently in the development process. Interested parties may present evidence and information during the meetings. Registration is required. Formal presentations (i.e. PowerPoint presentations, etc.) must be submitted at least seven days prior to the meeting. For more information, see our Open Meetings webpage.
CAC Engagement Meetings are for our CAC members to discuss and provide input on proposed LCDs to our CMDs and staff during the comment period. Registration is not required. The general public is invited to observe the Proposed LCD Discussion section in a listen-only capacity. For more information, see our Contractor Advisory Committee (CAC) Meetings webpage.
|
|